Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics, Inc. (CGEM) Healthcare & Pipeline Overview

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of oncology and immuno-oncology therapies. With a diverse pipeline including CLN-978, CLN-619, and Zipalertinib CLN-081/TAS6417, the company aims to address unmet needs in cancer treatment, positioning itself within a competitive pharmaceutical landscape.

What Is the Investment Thesis for CGEM?

Cullinan Therapeutics presents a notable research candidate within the biopharmaceutical sector, driven by its diverse pipeline of oncology and immuno-oncology therapies. The company's focus on innovative treatments targeting unmet needs in cancer positions it for potential growth. Key value drivers include the clinical progress of its lead drug candidates, such as CLN-978 and Zipalertinib CLN-081/TAS6417. Upcoming clinical trial results for these programs could serve as significant catalysts, potentially leading to increased valuation. However, the company faces inherent risks associated with clinical-stage drug development, including regulatory hurdles and potential setbacks in clinical trials. As of May 4, 2026, the company has a market capitalization of $1.09B.

Based on FMP financials and quantitative analysis

CGEM Key Highlights

• Cullinan Therapeutics focuses on oncology and immuno-oncology therapies.
• The company's pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617.
• Cullinan Therapeutics was founded in 2016.
• The company is headquartered in Cambridge, MA.
• Cullinan Therapeutics has a market capitalization of $1.09B.

Who Are CGEM's Competitors?

CGEM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CGEM's Key Strengths?

• Diverse pipeline of oncology and immuno-oncology therapies
• Focus on innovative treatments targeting unmet needs
• Experienced management team
• Strong intellectual property position

What Are CGEM's Weaknesses?

• Clinical-stage company with no currently marketed products
• Reliance on successful clinical trial outcomes
• High cash burn rate
• Competition from larger pharmaceutical companies

What Could Drive CGEM Stock Higher?

• Clinical trial data readouts for CLN-978 in hematological malignancies.
• Phase 2/3 trial results for Zipalertinib CLN-081/TAS6417 in NSCLC.
• Advancement of CLN-619 into combination therapy trials.
• Potential strategic partnerships and collaborations.

What Are the Key Risks for CGEM?

• Negative return on equity (-51.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or setbacks.
• Regulatory delays or rejections.
• Competition from established and emerging therapies.
• High cash burn rate and need for additional funding.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for CGEM?

• Growth opportunity 1: Advancing CLN-978, a novel T-cell engager, through clinical trials represents a significant growth opportunity. The market for T-cell engagers in oncology is expanding, with potential applications in various hematological malignancies. Positive clinical data could lead to partnerships or acquisitions, driving substantial value for Cullinan Therapeutics. The timeline for potential regulatory approval is estimated to be within the next 3-5 years, contingent on successful trial outcomes. The market size for T-cell engager therapies is projected to reach billions of dollars by 2030.
• Growth opportunity 2: The development of Zipalertinib CLN-081/TAS6417, a selective EGFR inhibitor, offers another key growth avenue. Targeting specific EGFR mutations in non-small cell lung cancer (NSCLC) could address a significant unmet need. Positive Phase 2/3 trial results could position Zipalertinib as a leading therapy in this space. The timeline for potential market entry is estimated within the next 2-4 years, pending regulatory approvals. The NSCLC therapeutics market is substantial, with targeted therapies representing a significant segment.
• Growth opportunity 3: Expanding the application of CLN-619, an IL-2 cytokine, into combination therapies with other immuno-oncology agents presents a growth opportunity. IL-2 cytokines can enhance anti-tumor immunity, and combining CLN-619 with checkpoint inhibitors or other immunomodulatory agents could improve treatment outcomes. Clinical trials evaluating these combinations are underway, with potential data readouts expected in the next 1-2 years. The immuno-oncology market is rapidly growing, with combination therapies becoming increasingly important.
• Growth opportunity 4: Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate the development and commercialization of Cullinan's pipeline assets. Partnering could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. Potential partners may be interested in licensing or co-developing Cullinan's drug candidates. These partnerships could materialize within the next 1-3 years, depending on clinical trial progress and strategic alignment.
• Growth opportunity 5: Expanding the pipeline through the acquisition or in-licensing of additional oncology and immuno-oncology assets represents a growth opportunity. Identifying and securing promising new drug candidates could diversify the company's portfolio and reduce its reliance on existing programs. This expansion could occur within the next 1-2 years, as Cullinan actively evaluates potential opportunities in the biopharmaceutical landscape.

What Opportunities Does CGEM Have?

• Positive clinical trial results for lead drug candidates
• Strategic partnerships and collaborations
• Expansion into new therapeutic areas
• Acquisition or in-licensing of additional assets

What Threats Does CGEM Face?

• Clinical trial failures
• Regulatory hurdles
• Competition from existing and emerging therapies
• Patent expirations

What Are CGEM's Competitive Advantages?

• Proprietary drug candidates with patent protection
• Scientific expertise in oncology and immuno-oncology
• Clinical data supporting efficacy and safety
• Strategic partnerships with pharmaceutical companies

What Does CGEM Do?

Cullinan Therapeutics, Inc., founded on September 15, 2016, by Patrick A. Baeuerle, is a clinical-stage biopharmaceutical company dedicated to developing a pipeline of oncology and immuno-oncology therapies. Headquartered in Cambridge, MA, the company focuses on creating innovative treatments for cancer patients. Cullinan's pipeline includes several drug candidates in various stages of development. Key programs include CLN-978, a novel T-cell engager designed to target specific cancer cells; CLN-619, an IL-2 cytokine designed to enhance anti-tumor immunity; Zipalertinib CLN-081/TAS6417, a selective EGFR inhibitor targeting specific mutations; CLN-049, a FLT3 inhibitor; and CLN-617, another immuno-oncology asset. The company's strategy involves identifying and developing promising therapeutic candidates with the potential to address significant unmet needs in cancer treatment. Cullinan Therapeutics operates primarily in the United States, focusing on preclinical and clinical development activities to advance its pipeline towards commercialization. The company's approach combines scientific expertise with a focus on translational medicine to deliver meaningful benefits to patients with cancer.

What Products and Services Does CGEM Offer?

• Develop oncology therapies
• Develop immuno-oncology therapies
• Conduct preclinical research
• Conduct clinical trials
• Focus on innovative cancer treatments
• Advance pipeline of drug candidates
• Target unmet needs in cancer treatment

How Does CGEM Make Money?

• Develop and commercialize oncology and immuno-oncology therapies.
• Generate revenue through product sales and licensing agreements.
• Partner with larger pharmaceutical companies for development and commercialization.
• Focus on clinical trials to demonstrate efficacy and safety of drug candidates.

What Industry Does CGEM Operate In?

Cullinan Therapeutics operates within the highly competitive biopharmaceutical industry, specifically focusing on oncology and immuno-oncology. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in cancer diagnostics. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech companies, all vying for market share. Cullinan Therapeutics differentiates itself through its focus on innovative therapies and a diverse pipeline of drug candidates targeting various cancer types. The company's success depends on its ability to navigate regulatory hurdles, secure funding, and demonstrate clinical efficacy in its ongoing trials.

Who Are CGEM's Key Customers?

• Cancer patients
• Healthcare providers
• Hospitals and cancer centers
• Pharmaceutical companies (potential partners)

CGEM Valuation & Market Position

With a $1.09B market cap, Cullinan Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, CGEM's quantitative score of 55/100 is below the peer average of 73/100.

FY2026 estForward Outlook

Wall Street analysts project Cullinan Therapeutics, Inc. revenue of about $17.8M for fiscal 2026, with EPS near $-3.03. The estimate reflects 7 contributing analysts.

F-Score 1/9Financial Health

Cullinan Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 14.61 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -51%Key Financial Metrics

Return on equity for Cullinan Therapeutics, Inc. stands at -51.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -20.5%, the inverse of the P/E and a quick read on earnings relative to price.

CGEM Financials

CGEM Latest News

CGEM Analyst Consensus

CGEM MoonshotScore

Common Questions About CGEM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources